GSDME and glioblastoma: As graphed in Figure 1A, the expression level of GSDME in malignant cancers of cholangiocarcinoma (CHOL), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), pheochromocytoma and paraganglioma (PCPG), stomach adenocarcinoma (STAD) is higher than their adjacent normal tissues (P<0.05).